Pharmacological effects of tiludronate in horses after long-term immobilization.

This study examined the effects of tiludronate, a drug used in veterinary medicine for bone disorders, on horses that were immobilized for a lengthy period. The researchers focused on how the drug impacted bone health, specifically looking at changes in bone metabolism markers and bone structure and density. The results showed that tiludronate significantly reduced bone loss during immobilization.

Research Methodology

• The study involved two groups, each containing eight horses. All horses were immobilized for an 8-week period by putting the left forelimbs of each horse in a fiberglass cast.
• The first group, referred to as the P-group, received a placebo treatment, while the second group, referred to as the T-group, received tiludronate at a dose of 1 mg/kg through slow intravenous infusion.
• There were two rounds of treatment administered to the horses, which were carried out 28 days apart.
• After immobilization, the horses underwent a 4-week remobilization period and an 8-week standardized training protocol.
• The researchers evaluated one biomarker of bone resorption – C-telopeptides of type I collagen cross-links (CTX-1), and one biomarker of bone formation – the bone isoenzyme of alkaline phosphatase (bone ALP).
• Bone mineral density (BMD) of the third metacarpus bone (MCIII) and speed of sound (SOS) were assessed using dual-energy X-ray absorptiometry (DEXA) and quantitative ultrasonography (QUS), respectively.

Results and Observations

• Only the T-group showed a rapid, transient, and significant decrease in CTX-1 concentrations after each treatment – an indicator of reduced bone resorption.
• There were no notable differences between the groups in terms of changes in bone ALP activity, a marker for bone formation.
• At the end of the experiment, DEXA measurements showed that the loss of Bone Mineral Density (BMD) in the immobilized limb of horses from the T-group was significantly less than that of the P-group, suggesting that tiludronate limited bone loss during immobilization.
• The speed of sound (SOS) measurements of MCIII obtained through QUS – an indicator of bone quality – showed no significant changes within or between groups.

Conclusions

• The results demonstrated that tiludronate significantly reduced bone resorption during the immobilization period and prevented long-term bone loss in the immobilized limb.
• The researchers concluded that Disuse Osteopenia – a condition where
  bone loss occurs due to less usage or inactivity – did not affect the lateral superficial cortex of MCIII.